Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
about
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesNovel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1RAS diseases in childrenCurrent management of juvenile myelomonocytic leukemia and the impact of RAS mutationsMutant Cbl proteins as oncogenic drivers in myeloproliferative disordersInhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignanciesCbl and human myeloid neoplasms: the Cbl oncogene comes of age.Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype.Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells.Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.Molecular targets for the treatment of juvenile myelomonocytic leukemia.Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia.UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemiaTargeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignanciesPathogenesis and consequences of uniparental disomy in cancer.Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.An evolutionary perspective on chronic myelomonocytic leukemia.Role of the ubiquitin proteasome system in hematologic malignancies.Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.The importance of regulatory ubiquitination in cancer and metastasis.CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy.Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemiaVAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.Oncogenic Signaling by Leukemia-Associated Mutant Cbl ProteinsMutational analysis of RNA splicing machinery components in 206 children with myeloid malignancies.In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia.Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.Origins of myelodysplastic syndromes after aplastic anemia.Molecular Diversity and Associated Phenotypic Spectrum of Germline CBL Mutations.Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder.
P2860
Q26752940-3D27B980-B40E-4346-A36F-FEC6383E483BQ27687464-104DE8C0-FF4B-4830-BF57-08671D019659Q28252058-02714540-ADFD-4CBF-9CBA-B66DB72077CDQ28263773-77AD6761-50DE-4468-904C-A9A99281E725Q28307750-DD280BF1-96F1-44D6-A0AB-35FB7D9EC533Q33774488-0C2B9FAE-6B06-4845-AC95-ED25B9FFD5A3Q33788643-6D07192C-15D9-47E3-866B-BA437384CFFCQ33925815-AE040CB5-50CA-4AE6-8149-91229C4B2037Q34050931-F2443D6B-224D-4F82-AE00-991DDDD6FB8FQ34136434-A69D7D1A-BE23-4053-AA48-247DA2EF6E72Q34155125-36A32784-F62E-479F-96B7-AC7CB2CEE040Q34310556-44B96AE1-E575-4127-B6C7-EFEC7715D951Q35030952-047877A9-138F-4EAE-BA0F-76D4B5B500C5Q35144330-B19141E2-280D-4015-9095-A2F05C6C8DFBQ35463260-1F043C3E-3370-4C95-97B7-E8B8C5E45819Q35579349-8CD1C87D-0A69-4C15-A105-2F3191936A31Q35882742-215E8EDC-F147-4273-A4C6-E1C716075686Q36642902-7DF293C3-9875-4498-B0F8-EB05EA2129E7Q36958309-50C5F2C1-9662-4D26-AA45-BA2B608C5B25Q37161507-64B3C490-59DF-4019-8633-125F7306AC41Q37868831-FEFB4E31-6A6E-40E3-B97B-B075B25F0EBBQ37979958-DB10FE3D-6137-4D88-AD4A-F91907CC84E1Q37993420-481BB6F3-D4A9-4F70-B8A5-BD0675DBA31EQ38096235-E7B42BC8-D285-4DB8-81D3-6FD3F6CF0ADDQ38289055-4757DF6A-B4CD-4C1A-B609-238AE42419C8Q38721532-C21D9C22-556F-4E80-83E9-12ED4FD59D84Q39048645-68BF8943-A24A-4946-9473-36C2CDCD9FA3Q39122602-AD998BE1-BFE5-4EE9-BCE8-E16F05B66232Q39148813-03FEB00F-9C9B-48AB-A14B-26BA15EF07F9Q39399799-F79277C6-BB2C-45D2-90DD-DDA7F34EB789Q41076612-CF44D49D-C9A3-4518-AFE6-9FA02D16D5D4Q41850026-5AA105AB-DDBF-4C41-B1C4-969C8BE3F9C7Q41906135-18D99DB5-0EB2-4D89-A80B-F28D27581E6EQ42160561-2B7CEEEC-7459-4F09-B69F-439E23A0D538Q42210837-694BA4CE-F29B-4CA0-8288-9249D72B97DBQ44390571-E9C63E7A-83EF-46D2-91B8-343139F4A679Q48557504-F8C0CA55-1927-4A21-93C0-07E3FFE2B316Q50147118-FC7DC1A5-B516-4AFC-836A-16053145A78EQ50587974-63AE4682-7DAF-4BA7-AC1C-AF51FCC5D0A4Q52654134-81AA88A6-E2D7-468F-BFAB-34F4EBD7058D
P2860
Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Mutations of an E3 ubiquitin l ...... enile myelomonocytic leukemia.
@ast
Mutations of an E3 ubiquitin l ...... enile myelomonocytic leukemia.
@en
type
label
Mutations of an E3 ubiquitin l ...... enile myelomonocytic leukemia.
@ast
Mutations of an E3 ubiquitin l ...... enile myelomonocytic leukemia.
@en
prefLabel
Mutations of an E3 ubiquitin l ...... enile myelomonocytic leukemia.
@ast
Mutations of an E3 ubiquitin l ...... enile myelomonocytic leukemia.
@en
P2093
P2860
P1433
P1476
Mutations of an E3 ubiquitin l ...... enile myelomonocytic leukemia.
@en
P2093
Anna M Jankowska
Asahito Hama
Atsushi Manabe
Christine O'Keefe
Heather Cazzolli
Hideki Makishima
Hideki Muramatsu
Hiroshi Yagasaki
Jaroslaw P Maciejewski
P2860
P304
P356
10.1182/BLOOD-2009-06-226340
P407
P577
2009-12-11T00:00:00Z